Company intelligence / Profile preview

Rigvir Holding

Ownership: Private
Development stage: Other

Overview

Rigvir (ECHO-7) is the first registered non-genetically modified oncolytic virus, approved in Latvia in 2004 for melanoma treatment. It has been used in clinical practice for over 20 years, included in Latvian national guidelines for skin cancer and melanoma, with ongoing efforts for EU registration and expansion.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapy
Industry: Biotech

Drug pipeline

1 asset

rigvir

Unknown

Partnerships

Guizhou Sinorda Biomedicine Co.Smart Nanovirus LimitedAramaPharm Ltd

Beyond the preview

Go deeper on Rigvir Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rigvir Holding.